News
FDA, Moderna COVID-19 vaccine
Digest more
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...
Zacks.com on MSN3h
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric PatientsModerna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback